Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Allergic Rhinitis, Asthma (Diagnosis)
Phase PHASE4
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls. STUDY OUTLINE The study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected. Following the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline. Allergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ALK Alutard SQ Dog — The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.

Primary Outcomes

  • Total nasal symptom score (TNSS) (Patients will be exposed to dog allergen at baseline and again after one year of treatment with Alutard SQ dog. TNSS will be assessed at both occasions.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-01
Completion: 2027-12-01
Eligibility
Age: 18 Years – 50 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Principal Investigators:
  • Lars Olaf Cardell (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet, Division of ENT
Contact Information
Study Contact:
Carl Skröder, MD
+46 41055181
carl.skroder@ki.com
Lars Olaf Cardell, Professor
lars-olaf.cardell@ki.se
Franziska Nordström, MD
+46704447341
franziska.nordstrom@skane.se
Lund University Hospital
Interventions
  • Drug: ALK Alutard SQ Dog — The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.
Study Locations (2 sites)
Lund University Hospital, Lund, Skåne County 23152 Sweden
Trelleborg Hospital, Trelleborg, Skåne County 23152 Sweden
Eligibility Criteria
Inclusion Criteria The subject has provided written informed consent to participate in the study. * Age 18-50 years. * Moderate-to-severe allergic symptoms upon exposure to dogs. * Dog allergy confirmed by positive specific IgE. * Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC). * Female subjects of childbearing potential must use adequate contraception. * A negative pregnancy test must be obtained prior to enrolment. Exclusion Criteria * Pregnancy or breastfeeding. * Autoimmune or connective tissue disease. * Cardiovascular disease. * Hepatic disease. * Renal disease. * Malignancy. * Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis). * Chronic obstructive or restrictive lung disease. * Treatment with medications that may interfere with the immune response. * Previous immunotherapy or chemotherapy. * Significant chronic disease. * Major metabolic disease. * Alcohol or substance abuse. * Mental or cognitive incapacity that may impair compliance with study procedures. * Known or suspected hypersensitivity to the study product. * Suspected or confirmed bacterial infection. * Clinically relevant allergy to house dust mite. * Current dog ownership. * Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate. * Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.
Conditions Asthma in Children
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized control trial is to learn if box fans and filters can reduce asthma symptoms and improve indoor air quality in children ages 6 - 17 years old with asthma living in the Duwamish Valley, Seattle, Washington. The main question it aims to answer are: * Do box fans with filters improve asthma symptoms? * Do box fans with filters improve an objective measure used to monitor lung function known as forced expiratory volume during the first second (FEV1)? Researchers will compare children living in households with high quality filters to those in households with sham filters to see if air quality and asthma symptoms improve. Participants will * fill out several questionnaires * monitor their lung function with a peak flow meter * place an air monitor in their homes to monitor indoor air quality * run the box fan when they are at home

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: MERV 13 filter — This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
  • Other: Sham filter — This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.

Primary Outcomes

  • Asthma symptoms (ACQ will be measured weekly for 6 consecutive weeks, two pre-intervention weeks (before box fans have been given to participant) and four weeks while fans are being used in the home. Symptoms will also be assessed at the six month follow-up visit.)
  • FEV1 (FEV1 measures will be taken daily, once in the morning and once at night for the six week study time frame. Prior to the six month follow up we will ask participants to take three consecutive days of FEV1 measurements, for an additional 6 measures)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-30
Completion: 2028-07
Eligibility
Age: 6 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: National Institute of Environmental Health Sciences (NIEHS)
Principal Investigators:
  • Anjum Hajat, PhD, MPH (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Anjum Hajat, PhD, MPH
206-685-3618
anjumh@uw.edu
Joseph Santana, MPH
253-235-9148
joseph@drcc.org
Duwamish River Community Coaltion
Interventions
  • Other: MERV 13 filter — This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
  • Other: Sham filter — This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
Study Locations (1 sites)
Duwamish River Community Coaltion, Seattle, Washington 98108 United States
Eligibility Criteria
Inclusion Criteria: * age (6-17 years) * poorly controlled physician diagnosed asthma defined as more than four days with asthma symptoms in the past two weeks, use of asthma rescue medication for more than four days in the past two weeks, or health care utilization due to asthma in the past year (hospitalization, emergency room visit, or unscheduled clinic visit) * living in Georgetown and South Park neighborhoods of Seattle Exclusion Criteria: * children with unstable housing or shared custody arrangements
Conditions Asthma
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Nocturnal worsening of asthma is common. It is characterized by overnight exacerbation of asthma symptoms such as shortness of breath, chest tightness, coughing, and wheezing, increased need of asthma medications and airway hyperresponsiveness, and decline in lung function (1). Nocturnal asthma has been attributed in part to circadian variations in lung function and airway inflammation. However, other factors including sleep, supine posture and lung volume may also contribute to nocturnal asthma. Current treatments often improve nighttime asthma symptoms. Nevertheless, nocturnal asthma is still common. Up to 2/3rd of asthma patients report nocturnal asthma symptoms, and many asthma related events occur at night, indicating poor asthma control. Results from an ongoing study suggest that in asthma while subjects were supine, fluid shifted out of the legs and accumulated in the thorax (rostral fluid shift) contributing to lower airway narrowing in asthma. A previou study has shown that wearing compression stockings during the day reduces fluid retention in the legs, reduces nocturnal rostral fluid shift out of the legs, and improves sleep apnea (2, 3). The aims of the proposed study is investigate whether off-the-shelf, below the knee compression stockings will attenuate nocturnal fluid shift and lower airway narrowing in asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Compression Stockings — We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
  • Other: Control — Participants will not wearing compression stockings for two weeks.

Primary Outcomes

  • Effect of wearing compression stockings on reducing rostral fluid shift during sleep and its effect in airway narrowing (After 2 weeks of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2017-02-21
Completion: 2026-08-31
Eligibility
Age: 20 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Principal Investigators:
  • Azadeh Yadollahi (PRINCIPAL_INVESTIGATOR) - Scientist
Contact Information
Study Contact:
Cristina O Francisco
416 597 3422
cristina.francisco@uhn.ca
Cristina Francisco, PhD
416 597 3422
cristina.francisco@uhn.ca
Toronto Rehabilitation Institute (TRI)
Azadeh Yadollahi, PhD
Toronto Rehabilitation Institute (TRI)
Interventions
  • Other: Compression Stockings — We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
  • Other: Control — Participants will not wearing compression stockings for two weeks.
Study Locations (1 sites)
Toronto Rehabilitation Institute (TRI), Toronto, Ontario M5G 2A2 Canada
Eligibility Criteria
Inclusion Criteria: non-smokers or former smokers (\<10 pack/year) Exclusion Criteria: uncontrolled hypertension
Conditions Asthma Acute
Phase NA
Enrollment 448
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is a common chronic bronchial disease affecting 300 million people worldwide. The disease can be severe when it is not managed properly or when it is not controlled by treatments. Asthma is characterized by bronchial inflammation, bronchial hyperreactivity and tissue remodeling. Symptoms include episodes of coughing, dyspnoea and wheezing in relation with bronchial obstruction. The evolution is marked by the occurrence of exacerbations (increase of symptoms), most often triggered by viral infections, mostly due to rhinoviruses. The treatment of asthma is based on inhaled corticosteroid therapy sometimes combined with other treatments that help control the majority of asthma. However, about 10% of patients suffer from persistent symptoms despite these treatments. Natural killer (NK) cells are important actors of the antiviral innate immune response and are present in high numbers in the lungs. However, their role in severe asthma and its virus-induced exacerbations is unknown. The purpose of this work is to characterize NK cells in severe asthma in order to identify molecules expressed differently from control subjects. The goal is to assess whether these molecules could be potential biomarkers of a severe asthma subtype, also known as the endotype, and/or be the molecular control for exacerbation. The advantage of identifying biomarkers for inflammatory diseases lies in their usefulness in establishing a correct diagnosis, monitoring the progress of the disease and the effectiveness of treatments. The secondary objectives are to characterize the activation of NK cells in response to in vitro rhinovirus infection of different types, in monoculture or in a model of interaction with a bronchial epithelium, and identify one or more molecules involved in the interaction between bronchial epithelial cells and NK cells.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Biological: blood sample — Blood sample (56mL) taken in a heparin tube

Primary Outcomes

  • Changes in expression of one or more molecules on the surface of NK cells (day 1 to day 2555)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-07
Completion: 2030-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 448 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Contact Information
Study Contact:
Pascal Chanez, PU-PH
+334.91.96.58.64
pascal.chanez@univ-amu.fr
Catherine Duez, CRCN
+334.91.32.42.74
catherine.duez@inserm.fr
Pascal CHANEZ, PU-PH
+334.91.96.58.64
pascal.chanez@univ-amu.fr
Hôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du sommeil
Interventions
  • Biological: blood sample — Blood sample (56mL) taken in a heparin tube
Study Locations (1 sites)
Hôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du sommeil, Marseille, 13915 France
Eligibility Criteria
Inclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: * Consent form read, understood, approved and signed before any study procedure * Membership of a social security scheme or beneficiary of such a scheme * Patient aged over 18 Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation: \- Diagnosis of severe asthma confirmed by a respirologist at an expert centre Case asthma controlled: \- Asthma control confirmed by a lung specialist from an expert centre Case uncontrolled asthma excluding exacerbation: \- Uncontrolled asthma confirmed by a lung specialist from an expert centre Case uncontrolled asthma with exacerbation: \- Current exacerbation Exclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: * Person subject to a legal protection measure * Vulnerable population: minors, persons under guardianship or trusteeship or persons deprived of their rights to liberty by court order. * women with a known pregnancy * Inability or refusal to comply with research requirements * Active or weaned smoker \> 15 PA * Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or opioids in the 10 days prior to inclusion Case patient with asthma: \- Coexistence of a chronic inflammatory disease other than asthma Case healthy volunteers: \- Coexistence of an inflammatory pathology Exclusion criteria: Cases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU/L (measured on the study sample)
Conditions Depression, Cancer
Phase NA
Enrollment 86
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Cancer-related depression (CRD) is a common psychological condition among cancer patients during diagnosis, treatment, and recovery, and is associated with reduced quality of life, impaired immune function, and poorer clinical outcomes. As cancer incidence and mortality continue to rise in China, the psychological burden on patients is receiving increasing attention. Electroacupuncture (EA) has shown potential in treating various types of depression and related somatic symptoms, but evidence regarding its efficacy, safety, and long-term effects in CRD remains limited. This randomized controlled trial aims to evaluate the short- and long-term efficacy and safety of EA for CRD, with the goal of providing evidence to support effective and optimized treatment strategies.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Electroacupuncture treatment — Participants in this group will receive electroacupuncture (EA) based on a semi-standardized protocol. Each treatment session will involve needling at six main acupoints and two supplementary points, selected based on individual symptoms. * Main acupoints: Baihui (GV20), Yintang (EX-HN3), Guanyuan (CV4), Qihai (CV6), bilateral Zusanli (ST36), bilateral Sanyinjiao (SP6). * Supplementary acupoints: Selected from Shenting (GV24), Sishencong (EX-HN1), Fengchi (GB20), Neiguan (PC6), Hegu (LI4), Shenmen (HT7), Yanglingquan (GB34), Taixi (KI3), and Taichong (LR3). All patients will be placed in the supine position. After routine disinfection of all acupoints using 75% alcohol, needles will be inserted using a gentle tapping technique. Once Deqi sensation is achieved, three pairs of electrodes from an EA device will be connected to the handles of the needles at Baihui and Yintang, and bilaterally at Zusanli and Sanyinjiao. Each treatment session will last for 30 minutes.
  • Other: Superficial acupuncture at Non-Acupoints — Participants in this group will receive superficial acupuncture at six pseudo-acupoints that do not correspond to any recognized meridian or traditional acupoint. These points are anatomically matched in location (head, upper limbs, lower limbs, and trunk) to the main acupoints used in the EA group but are located at non-meridian, non-acupoint sites in a horizontal position. Acupuncture needles will be connected to an electroacupuncture device with broken wires and thus no electrical stimulation is actually delivered. All patients will be placed in a supine position. After routine disinfection of the selected sites using 75% alcohol, sterile disposable filiform needles (0.22 × 25 mm) will be lightly inserted to a depth of approximately 3 mm without requiring deqi. The needles will be applied using a gentle tapping technique at non-meridian, non-acupoint locations. The needle will be retained for 30 minutes. The session frequency and total treatment course will match the EA group.
  • Other: Standard care — All participants, regardless of group assignment, will receive standard care as part of routine oncological and psychological management. Standard care includes: * Basic psychological support: General psychological counseling or emotional support provided by nursing staff or clinical psychologists as needed, without structured psychotherapy or pharmacological antidepressant interventions unless clinically indicated. * Health education: Guidance on sleep hygiene, nutrition, and stress management, along with education about cancer-related emotional symptoms and coping strategies. * Medication management: Participants will continue their current medications for chronic comorbidities (e.g., antihypertensives, antidiabetics) as previously prescribed. However, cancer-related medications associated with active treatment-such as chemotherapy, targeted therapies, immunotherapy, or hormonal therapy-will be excluded during the trial period to avoid confounding effects.

Primary Outcomes

  • Hamilton Depression Rating Scale - 17 items (Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2027-07-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Municipal Hospital of Traditional Chinese Medicine
Principal Investigators:
  • Shifen Xu, Doctor (STUDY_DIRECTOR) - SHMTCM's Acupuncture Department
Contact Information
Study Contact:
Xuan Yin, Doctor
86-18939916330
yinxuan0623@hotmail.com
Tao Guo, Master
86-15047856427
guotao2000@126.com
XUAN YIN
Shanghai Municipal Hospital of Traditional Chinese Medicine
Interventions
  • Device: Electroacupuncture treatment — Participants in this group will receive electroacupuncture (EA) based on a semi-standardized protocol. Each treatment session will involve needling at six main acupoints and two supplementary points, selected based on individual symptoms. * Main acupoints: Baihui (GV20), Yintang (EX-HN3), Guanyuan (CV4), Qihai (CV6), bilateral Zusanli (ST36), bilateral Sanyinjiao (SP6). * Supplementary acupoints: Selected from Shenting (GV24), Sishencong (EX-HN1), Fengchi (GB20), Neiguan (PC6), Hegu (LI4), Shenmen (HT7), Yanglingquan (GB34), Taixi (KI3), and Taichong (LR3). All patients will be placed in the supine position. After routine disinfection of all acupoints using 75% alcohol, needles will be inserted using a gentle tapping technique. Once Deqi sensation is achieved, three pairs of electrodes from an EA device will be connected to the handles of the needles at Baihui and Yintang, and bilaterally at Zusanli and Sanyinjiao. Each treatment session will last for 30 minutes.
  • Other: Superficial acupuncture at Non-Acupoints — Participants in this group will receive superficial acupuncture at six pseudo-acupoints that do not correspond to any recognized meridian or traditional acupoint. These points are anatomically matched in location (head, upper limbs, lower limbs, and trunk) to the main acupoints used in the EA group but are located at non-meridian, non-acupoint sites in a horizontal position. Acupuncture needles will be connected to an electroacupuncture device with broken wires and thus no electrical stimulation is actually delivered. All patients will be placed in a supine position. After routine disinfection of the selected sites using 75% alcohol, sterile disposable filiform needles (0.22 × 25 mm) will be lightly inserted to a depth of approximately 3 mm without requiring deqi. The needles will be applied using a gentle tapping technique at non-meridian, non-acupoint locations. The needle will be retained for 30 minutes. The session frequency and total treatment course will match the EA group.
  • Other: Standard care — All participants, regardless of group assignment, will receive standard care as part of routine oncological and psychological management. Standard care includes: * Basic psychological support: General psychological counseling or emotional support provided by nursing staff or clinical psychologists as needed, without structured psychotherapy or pharmacological antidepressant interventions unless clinically indicated. * Health education: Guidance on sleep hygiene, nutrition, and stress management, along with education about cancer-related emotional symptoms and coping strategies. * Medication management: Participants will continue their current medications for chronic comorbidities (e.g., antihypertensives, antidiabetics) as previously prescribed. However, cancer-related medications associated with active treatment-such as chemotherapy, targeted therapies, immunotherapy, or hormonal therapy-will be excluded during the trial period to avoid confounding effects.
Study Locations (1 sites)
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Presence of depression attributed to cancer itself or cancer-related treatments, meeting the diagnostic criteria for depressive disorder(DSM-V). 2. Age between 18 and 75 years, regardless of sex. 3. Hamilton Depression Rating Scale-17 (HDRS-17) total score \>17 at baseline. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. 5. No previous exposure to acupuncture treatment. 6. Ability to understand the study procedures and willingness to provide written informed consent. Exclusion Criteria: 1. Planned to undergo surgery, chemotherapy, radiotherapy, immunotherapy, or other active cancer-related treatments during the study period. 2. History of major depressive episodes prior to cancer diagnosis. 3. Pain Rating Index (PRI) score ≥4 due to cancer-related pain. 4. Estimated life expectancy of 12 months or less. 5. Presence of severe ulcers, abscesses, or active skin infections at or near the acupuncture sites. 6. Clinically significant dysfunction of major organs, including severe cardiac, cerebral, hepatic, renal impairment; decompensated pulmonary disease; or other serious systemic illnesses. 7. Pregnant or breastfeeding women. 8. Participation in another clinical trial within the past 30 days. 9. Patients with a cardiac pacemaker or other implanted electronic medical devices.

Leucine in Midlife Depression

NCT06580145
Recruiting
Conditions Major Depression
Phase PHASE2
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to investigate the effects of a 6-week leucine challenge on brain chemistry, connectivity, and behavior in people with midlife depression. The researchers will compare the leucine and an active comparator arm (lysine) for 6 weeks.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: L-leucine — L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1). The proposed dose for L-leucine is 4.31 g/day, administered orally.
  • Drug: L-lysine — L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters. The proposed dose for L-lysine is 6 g/day, administered orally

Primary Outcomes

  • Change in Glutamate (Baseline, Week 1, Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-01
Completion: 2029-06
Eligibility
Age: 35 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Ebrahim Haroon, MD (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Ebrahim Haroon, MD
(404) 727-8229
eharoon@emory.edu
Diana Beltran, BS
404-712-7686
djbeltr@emory.edu
Ebrahim Haroon, MD
404-712-2890
eharoon@emory.edu
Emory University Hospital
Interventions
  • Drug: L-leucine — L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1). The proposed dose for L-leucine is 4.31 g/day, administered orally.
  • Drug: L-lysine — L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters. The proposed dose for L-lysine is 6 g/day, administered orally
Study Locations (1 sites)
Emory University Hospital, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * Able and willing to provide informed consent * Diagnosis of major depression per Structured Interview for DSM-V (SCID-V) * Moderate to severe depression- Inventory of Depressive Symptoms - Self Reported (IDS-SR score \>34). * SHAPS score \>30 on the 0-56 scale * Body mass index (BMI) between 20-35 kg/m2 * Plasma CRP \>1 mg/L * No contraindications to MRI * Availability of friends or family for transportation after lumbar puncture procedure * Clinically significant findings on EKG * Patient Health Questionnaire (PHQ-9) score greater than 10 * Willingness to adopt contraceptive measures. Persons exempt from contraception requirements are: * Persons assigned male at birth * Persons assigned female at birth who: * have undergone a hysterectomy or bilateral oophorectomy; or * have been naturally postmenopausal for at least 24 consecutive months (i.e., has NOT had menses at any time in the preceding 24 consecutive months) Exclusion Criteria: * Leucine-Specific: * History of maple syrup urine disease * Risk of hypoglycemia (unstable diabetes) * History of vitamin B6 deficiency, relative * Lysine-Specific: * On calcium supplements, relative * History of renal/gall stones (could cleared by a primary care provider) * Cognitive: --Cognitive impairment (MMSE score \&lt;28) * Psychiatric Disorders: * Lifetime diagnosis of psychotic disorders. * Current mania/hypomania. * Substance use disorder in the last 6 months. * Active suicidal ideation: * Psychiatric hospitalization in the past year. * Suicide attempts within the last five years. * Scores \>3 on the Columbia Suicide Severity Rating Scale (C-SSRS) * Binge eating in the absence of mood symptoms increases. * Primary diagnosis of severe DSM-V79 anxiety disorders. * Primary diagnosis of DSM-V PTSD (if severity exceeds major depression). * Primary diagnosis of DSM-V obsessive-compulsive disorders. * Significant personality disorders with multiple hospitalizations or suicide attempts. * Developmental disorders (e.g., ADHD). * Concomitant medications: * Immune-active medications (e.g., non-steroidal anti-inflammatory agents). * Antibiotics and immunizations in the past 2 weeks. * Topical or inhaled steroids within the past week. * Oral/parenteral steroids in the last 6 months. * Supplements that impact the immune system (e.g., omega-3, probiotics) within the past 2 weeks. * Psychotropic medications within the last 4 weeks (8 weeks for fluoxetine). * Daily use of sedative-hypnotics, benzodiazepines, and opiates. * Medical Disorders: * Unstable medical disorders (frequent provider or medication changes). * Lifetime diagnosis/treatment of cancers (excluding basal cell carcinoma). * Lifetime diagnosis/treatment of autoimmune disorders. * Lifetime exposure to chemotherapeutic agents. * MRI Considerations: \-- Location and quantity of metallic objects safe to MR * Concomitant Treatment for Depression: \-- Treatments with antidepressant medications or those with antidepressant effects (dopamine supplements). * Treatment for General Medical Conditions (GMCs): * Stabilized medications are allowed if maintained at the same dose during the trial. * Multiple recent changes in concomitant medications reviewed by the study PI * Population * Pregnant women. * Children. * Prisoners. * Individuals unable to consent
Conditions Depression Chronic, Depression and Quali...
Phase PHASE1
Enrollment 608
Locations 3 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if ThIA Suivi, a digital tool for remote monitoring of patients, can improve the care of adults with depression who are followed by a psychiatrist. The main question it aims to answer is: \* Does using ThIA Suivi in addition to usual psychiatric care increase the proportion of patients whose depression symptoms have clearly improved after 3 months, compared with usual care alone? (Improvement is measured with a questionnaire on depression symptoms, the PHQ-9, and is defined as a drop of at least 5 points from the starting score.) Researchers will compare patients who use ThIA Suivi with patients who receive usual care only, to see if ThIA Suivi leads to a greater improvement in symptoms. The researchers' hypothesis is that patients using ThIA Suivi will do better. \[ Participants will: * Continue to be followed by their psychiatrist as usual. * Use ThIA Suivi or will receive usual care only * Complete questionnaires about their symptoms at 3 months, 6 months and 12 months. * Be followed for 12 months. Why is this study needed? Depression is a common mental health condition. It causes lasting sadness, loss of interest in everyday activities, and low energy. About 280 million people worldwide live with depression. It affects daily life, work, and relationships, and it can come back: more than half of people who have one episode will have another. Depression is often treated with antidepressant medication. However, after 8 weeks of treatment, only about 1 in 3 people fully recovers. Side effects can appear before the benefits, which can make it hard to keep taking the medication. Close follow-up after treatment starts is therefore important. In practice, the first follow-up visit often happens late (a median of 27 days after the prescription in France). In addition, psychiatrists are not evenly spread across France, and most first antidepressant prescriptions are written by general practitioners. Digital tools may help patients and health professionals stay in contact between visits. In France, however, no remote monitoring tool for mental health is currently reimbursed by the national health insurance. ThIA Suivi was developed by ThIA Santé Mentale to fill this gap. It is meant to be used within a care pathway supervised by health professionals. The researchers hope that it will improve patients' care, help them stay on track with treatment, and reduce the risk of the depression coming back.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Use of ThIA Medical Device — As soon as the patient has provided free and informed consent, signed it, he or she will be randomized and assigned to one of the two study arms: standard care combined with ThIA Suivi remote medical monitoring, or standard care alone. Regardless of which randomization arm he or she is assigned to, the patient will receive optimal care. The patient in this arm will have access to the "ThIA Suivi" remote medical monitoring system starting the days following their medical consultation with the psychiatrist and throughout his/her participation in the study, in addition to his/her usual standard of care. The patient will have access to all the features of the ThIA Suivi app, including personalized therapeutic education, standardized questionnaires to assess mental health, an alert and notification system, as well as monitoring of side effects and treatment adherence. This system will enable real-time monitoring of symptom progression, allowing the psychiatrist to intervene quickly.

Primary Outcomes

  • Number of Participants with A Reduction of 5 Points in PHQ-9 Score (From enrollment to 6 months after)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 608 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ThIA Santé Mentale
Collaborators: Digital Medical Hub
Contact Information
Study Contact:
Nicolas Desrumaux, PhD
0033684979459
admin@digitalmedicalhub.com
Jacques Boulet
0033668667725
jacques.boulet@digitalmedicalhub.com
Denis Boucaud-Maître, PhD, HDR
0033400000000
Denis.boucaud-maitre@ch-le-vinatier.fr
Centre Hospitalier Le Vinatier
Interventions
  • Device: Use of ThIA Medical Device — As soon as the patient has provided free and informed consent, signed it, he or she will be randomized and assigned to one of the two study arms: standard care combined with ThIA Suivi remote medical monitoring, or standard care alone. Regardless of which randomization arm he or she is assigned to, the patient will receive optimal care. The patient in this arm will have access to the "ThIA Suivi" remote medical monitoring system starting the days following their medical consultation with the psychiatrist and throughout his/her participation in the study, in addition to his/her usual standard of care. The patient will have access to all the features of the ThIA Suivi app, including personalized therapeutic education, standardized questionnaires to assess mental health, an alert and notification system, as well as monitoring of side effects and treatment adherence. This system will enable real-time monitoring of symptom progression, allowing the psychiatrist to intervene quickly.
Study Locations (3 sites)
Centre Hospitalier Le Vinatier, Bron, 69678 France
Hôpital Novo, Pontoise, 95300 France
Hôpital Uzès - Le Mas Careiron Secteur 30G07 - CMP de Saint Hippolyte du Fort, Uzès, 30700 France
Eligibility Criteria
Inclusion Criteria: * Patients with a PHQ-9 score of ≥ 15 and a confirmed diagnosis of depression * Patients under the care of the investigator; * Patients who have not received any treatment for at least 6 weeks and to whom the investigator prescribes an antidepressant. * Patients with a smartphone, computer or tablet with internet access; * Patients covered by a health insurance scheme; * Patients able to read and understand French; * Patients who have signed a written, informed consent form in person to take part in the study. Exclusion Criteria: * Patients under guardianship, curatorship or judicial protection, or subject to any other administrative or judicial measure resulting in the deprivation of rights and freedoms; * Patients with neurocognitive disorders or psychiatric conditions (e.g. psychotic disorders, cognitive impairments or manic states) that may compromise their ability to give free and informed consent and/or to comply with the study protocol; * Patients at imminent risk of suicide or with severe depression accompanied by psychotic symptoms; * Patients deemed non-autonomous by the psychiatrist, i.e. those who, according to clinical assessment, are unable to manage their daily activities independently or lack sound judgement; * Patients already enrolled in another interventional study * Vulnerable persons as defined in Articles L. 1121-5 to 8 and L. 1122-1-2 of the French Public Health Code are excluded from the study.
Conditions Anxiety Disorders, Depressive Disorder, ...
Phase NA
Enrollment 198
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test the efficacy of a transdiagnostic Internet-delivered interventions for Romanian adolescents with anxiety and/ or depression. The main questions it aims to answer are: * What is the clinical efficacy of the Internet-delivered intervention? * How accurate is the prediction model in predicting who will respond to treatment? Participants will undergo non-invasive fMRI to measure variability in brain signal as a proxy of the neural systems' adaptability before receiving the intervention, then they will be allocated either to the Internet-delivered intervention or control group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Transdiagnostic Internet-delivered intervention — The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.

Primary Outcomes

  • Internalizing problems (baseline, after 8 weeks of intervention, 6 months follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2026-06-30
Eligibility
Age: 13 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 198 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Babes-Bolyai University
Principal Investigators:
  • Costina Poetar, PhD (STUDY_CHAIR) - Babeș-Bolyai University
Contact Information
Study Contact:
Kristoffer Mansson, PhD
+46705803267
nils.mansson@ubbcluj.ro
Costina R Poetar, Ph.D
+ 40743589465
costinapoetar@psychology.ro
Babes-Bolyai University
Costina R Poetar, Ph.D
Babes-Bolyai University
Interventions
  • Behavioral: Transdiagnostic Internet-delivered intervention — The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.
Study Locations (2 sites)
Babes-Bolyai University, Cluj-Napoca, 400015 Romania
Babeș-Bolyai University, Cluj-Napoca, 400015 Romania
Eligibility Criteria
Inclusion Criteria: * elevated symptoms of anxiety or depression/ internalizing problems (T score\> 60) at intake (based on Youth self-report completed by adolescents) * primary diagnosis of an anxiety/depressive disorder based on DSM-5 criteria according to ADIS-5-C/P interview * age 13-17 * able to read and understand Romanian language * Currently unmedicated or on stable and adequate doses of medication for at least 6 weeks before treatment onset * Internet access Exclusion Criteria: * severe mental disorder (psychosis, severe depression, bipolar disorder, based on clinical interview) * any condition that interferes with the protocol implementation (e.g., physical illness or sensory impairment that interferes with behavioral tasks such as exposure, behavioral activation, unavailable for the next 3 months), * active suicidal ideation (assessed by child psychiatrist during clinical interview) in the last month * currently following CBT/ psychotherapy for anxiety/depression, in the last 6 months * fMRI incompatible (based on safety questionnaire) * Being diagnosed with an intellectual disability, pervasive developmental disorder, an alcohol and/or substance dependence disorder, reading disabilities (based on clinical interview). * Current treatment with benzodiazepines
Conditions Depression, Anxiety
Phase Not Applicable
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine the incidence,development trajectory and risk factors of the main peripartum mental health problems as well as explore its adverse outcomes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change of prevalence of maternal prenatal depression (before 20th gestational week, after 33th gestational week and prior to delivery)
  • Change of prevalence of maternal postpartum depression in the first year after delivery (6 weeks, 6 months and 1 year after delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2012-02-01
Completion: 2038-12-31
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangzhou Women and Children's Medical Center
Principal Investigators:
  • Xiu Qiu, PhD (PRINCIPAL_INVESTIGATOR) - Guangzhou Women and Children's Medical Center
Contact Information
Study Contact:
Xiu Qiu, PhD
0086 20 38367160
qxiu0161@163.com
Dongmei Wei, MSc
0086 20 38367159
Xiu Qiu, PhD
qxiu0161@163.com
Guangzhou Women and Children's Medical Center
Interventions
N/A
Study Locations (1 sites)
Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510623 China
Eligibility Criteria
Inclusion Criteria: 1. Pregnant women with \<20 weeks of gestation 2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center 3. Permanent residents or families intended to remain in Guangzhou with their child for more than 3 years Exclusion Criteria: 1. Combined with heart disease, hypertension, diabetes or hyperthyroidism 2. Taking anti-depressants and other treatments for depression 3. Participants was in infection status when the biological samples were collected
Conditions Anxiety Disorders and Symptoms, Depressi...
Phase NA
Enrollment 1800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Digital mental health interventions are a cost-effective and efficient approach to expanding the accessibility and impact of psychological treatments; however, little guidance exists for selecting the most effective program for a given individual. In the proposed study, decision rules will develop for selecting the digital program that is most likely to be the optimal intervention for each user. These treatment recommendations can be implemented in the context of large healthcare delivery systems to improve the delivery of digital mental health interventions at scale. The overarching aim of the current study is to better understand for whom and how leading digital interventions work in a large healthcare setting. The study builds on the existing literature and follows expert recommendations by using machine learning (ML) methods to develop precision treatment rules (PTRs) for three leading digital interventions for emotional disorders (e.g., anxiety, depression, and related mental health disorders). Specifically, ML methods will be used to develop PTRs to optimize clinical outcomes and associated intervention engagement. This study will leverage a unique partnership between Boston University (BU), SilverCloud Health (SC)--a leading provider of digital mental health care--and Kaiser Permanente (KP)--one of America's leading health care providers. A clinical trial (RCT) will be conducted to evaluate the relative effectiveness of three distinct empirically supported digital mental health interventions (from SC's existing library of programs) in a sample recruited from KP primary care and other clinical settings. Data from this trial will be used to develop theoretically and empirically informed, reliable selection algorithms for managing treatment delivery decisions. Algorithms will be validated in a separate "holdout" dataset by examining whether allocation to predicted optimal treatment is associated with superior outcomes compared to allocation to a non-optimal treatment. The role of user engagement will be determined, and other mechanisms in treatment outcome.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) — This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
  • Behavioral: Space for depression — Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
  • Behavioral: Space for resilience — This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.

Primary Outcomes

  • Change from baseline well-being at week 12 (Baseline, 4-weeks following baseline, 8-weeks following baseline, and 12-weeks following baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-12
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston University Charles River Campus
Collaborators: National Institute of Mental Health (NIMH), Silver Cloud Health, Kaiser Permanente
Principal Investigators:
  • Todd Farchione, Ph.D. (PRINCIPAL_INVESTIGATOR) - Boston University Charles River Campus
Contact Information
Study Contact:
Todd Farchione, Ph.D.
(617) 353-9610
tfarchio@bu.edu
Anthony Rosellini, Ph.D.
(617) 353-9610
ajrosell@bu.edu
Todd Farchione, Ph.D.
617-353-9610
tfarchio@bu.edu
Center for Anxiety and Related Disorders
Interventions
  • Behavioral: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) — This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
  • Behavioral: Space for depression — Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
  • Behavioral: Space for resilience — This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
Study Locations (1 sites)
Center for Anxiety and Related Disorders, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * English-speaking adults * Ages 18 or older * Have a device that can connect to the internet.
Conditions Treatment Resistant Depression (TRD)
Phase NA
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic. Participation in the study will involve adding coaching sessions to your existing ketamine maintenance treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Psychedelic Integration Coaching — Participation in the study will involve adding coaching sessions to existing ketamine maintenance treatment for patients receiving ongoing maintenance IV ketamine or IN esketamine treatment at MGH's Ketamine Clinic. If participants are eligible, they will be invited to participate in 12 weekly, 50-minute one-on-one coaching sessions conducted via Zoom. These sessions are designed to help participants process and integrate their experiences with ketamine treatment, to support personal growth and symptom improvement. The coaching is non-clinical, collaborative, and participant-directed, and is provided by trained psychedelic integration coaches from the Fireside Project. Throughout the 3-month coaching period and again at a 1-month follow-up, participants will complete monthly study visits that include brief remote assessments with a study clinician, along with additional self-report questionnaires. These visits will take approximately 1 to 2 hours, depending on the time point.

Primary Outcomes

  • To assess the feasibility of adjunctive coaching during ketamine/esketamine maintenance treatment. (From enrollment to the end of treatment at Month 3)
  • To assess the acceptability of adjunctive coaching during ketamine/esketamine maintenance treatment. (From enrollment to the end of treatment at Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-17
Completion: 2028-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Fireside Project
Principal Investigators:
  • Maren Nyer, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital and Harvard Medical School
  • Franklin King, MD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital and Harvard Medical School
  • David Mischoulon, MD/PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital and Harvard Medical School
Contact Information
Study Contact:
Maren Nyer, PhD
6176434897
mnyer@mgh.harvard.edu
Franklin King, MD
fking@mgh.harvard.edu
Maren Nyer, PhD
6176434897
mnyer@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Behavioral: Psychedelic Integration Coaching — Participation in the study will involve adding coaching sessions to existing ketamine maintenance treatment for patients receiving ongoing maintenance IV ketamine or IN esketamine treatment at MGH's Ketamine Clinic. If participants are eligible, they will be invited to participate in 12 weekly, 50-minute one-on-one coaching sessions conducted via Zoom. These sessions are designed to help participants process and integrate their experiences with ketamine treatment, to support personal growth and symptom improvement. The coaching is non-clinical, collaborative, and participant-directed, and is provided by trained psychedelic integration coaches from the Fireside Project. Throughout the 3-month coaching period and again at a 1-month follow-up, participants will complete monthly study visits that include brief remote assessments with a study clinician, along with additional self-report questionnaires. These visits will take approximately 1 to 2 hours, depending on the time point.
Study Locations (2 sites)
Massachusetts General Hospital's Depression and Clinical Research program, Boston, Massachusetts 02114 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older at the time of informed consent/study enrollment. 2. Ability to understand and provide informed consent. 3. Fluent in English (spoken and written). 4. Willingness to have coaching sessions recorded via HIPAA-compliant MGB approved video-based platform. 5. Has a QIDS-SR score ≥ 11, indicating at least moderate depressive symptom severity at screening visit. 6. Lifetime diagnosis of a depressive disorder according to the MINI. 7. In the maintenance phase of ketamine or esketamine treatment, defined as the period following the initial acute treatment series (typically 2 treatments per week for 3 weeks). 8. Patients must have completed at least 3 maintenance treatments prior to screening visit with a QIDS-SR score ≥ 11 noted from EPIC medical records from the 3 most recent maintenance treatments. 9. Currently receiving maintenance IV ketamine or intranasal esketamine at the MGH Ketamine Clinic, with at least one treatment administered within the past 8 weeks, and planning to continue to be an active patient at the MGH Ketamine Clinic for the duration of the study. 10. Has established care with a mental health provider (e.g., psychiatrist, therapist, or other licensed mental health clinician), and, if outside the MGB-healthcare system, agrees to sign a Release of Information form (ROI) with the study team. Exclusion Criteria: 1. Presence of an unstable medical condition, as determined by the study clinician. 2. Significant neurocognitive impairment that impairs with individual's ability to maintain ADLs and would interfere with study participation, per study clinician judgment. 3. Newly initiated psychotherapy within the past 3 months. 4. Any condition or circumstance that, in the judgment of the Principal Investigator, makes participation unsafe or unsuitable. 5. Any psychiatric condition that is currently primary, clinically predominant to their depression, or insufficiently stable such that it would interfere with study participation, per clinician judgment. 6. Plan to switch from IV ketamine treatment to intranasal esketamine or plan to switch from intranasal esketamine to IV ketamine treatment at any point during study. 7. Suicidality determined by the judgment of the study clinicians at screen, with a plan to act in next 6 months. 8. A ≥25% reduction in QIDS total score from screen to baseline visit.
Conditions Angling, Supportive Therapeutic, Schizop...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effects of recreational fishing (angling) as a supportive therapeutic intervention in individuals diagnosed with schizophrenia. Schizophrenia is a chronic psychiatric disorder characterized by disturbances in thinking, perception, emotion, and behavior, often accompanied by negative symptoms such as social withdrawal, anhedonia, and cognitive impairment, which significantly reduce quality of life. Recreational activities, particularly those involving nature-based engagement, have been shown to support psychological well-being through stress reduction, improved attention, and enhanced mood regulation. Angling is considered a mindfulness-like recreational activity that promotes relaxation, concentration, and emotional regulation, potentially offering benefits for individuals with psychiatric conditions. In this randomized controlled study, participants with schizophrenia will engage in a structured recreational fishing program in addition to standard care. The effects of the intervention will be evaluated on biochemical serum parameters, anxiety and depression levels, and quality of life outcomes. The study also aims to assess the psychosocial well-being of participants and determine the feasibility of integrating angling as an adjunctive non-pharmacological intervention in schizophrenia care. The findings are expected to contribute to evidence-based complementary treatment approaches in psychiatric rehabilitation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: recreational fishing (angling) — Fishing will be done.

Primary Outcomes

  • The Positive and Negative Syndrome Scale (Baseline and immediately after the 8-week intervention.)
  • Quality of Life Scale for Schizophrenia Patients (Baseline and immediately after the 8-week intervention.)
  • UCLA Loneliness Scale (Baseline and immediately after the 8-week intervention.)
  • Serum Beta-Endorphin Concentration (Baseline and immediately after the 8-week intervention.)
  • Serum Serotonin Concentration (Baseline and immediately after the 8-week intervention.)
  • Serum Cortisol Concentration (Baseline and immediately after the 8-week intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-15
Completion: 2026-08-15
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Firat University
Contact Information
Study Contact:
Gülcan B Bahçecioğlu Turan
506 557 60 86
gulcanbahcecioglu@firat.edu.tr
Fırat university
Interventions
  • Behavioral: recreational fishing (angling) — Fishing will be done.
Study Locations (1 sites)
Fırat university, Elâzığ, Center 25240 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Able to communicate verbally * Diagnosed with schizophrenia * Able to provide written informed consent Exclusion Criteria: * Presence of comorbid psychiatric disorders other than schizophrenia * Patients in the acute psychotic (attack) phase